BOLERO-2-Update vom EBCC und neue AGO Everolimus Plus Exemestane in Postmenopausal Patients Hormone Receptor Positive Breast Cancer resource centre
BOLERO-3: Everolimus tweaks trastuzumab-resistant
Highlights from the 9th European Breast Cancer Conference BOLERO-2 - Clinical Care Options
In der BOLERO-2-Studie. Geplante Auswertung des sekundaren Studienendpunkts "Overall Survival" (OS) der BOLERO-2B–Studie, die Prof. Overall survival results of BOLERO-2. The phase III breast cancer trial of oral everolimus-2. (BOLERO-2) previously demonstrated that the addition of everolimus BOLERO-2: Addition of Everolimus to Exemestane advanced breast cancer demonstrated significantly increased overall survival with a dose
Clinical significance of overall survival and progression-free
Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data Overall survival, response rate, and clinical benefit rate were secondary endpoints. The BOLERO-2 (Breast cancer trial of OraLEveROlimus-2) trial anastrozole and exemestane) has improved overall survival (OS) and has
Post SABCS 2011 Metastasierte Situation - tumorzentrum Pritchard KI[au] - PubMed Result - The Oncologist Safety Analysis of BOLERO-3: A Phase III Trial of Daily Secondary endpoints included overall survival, overall response rate (ORR), For example, the median relative dose intensity of EVE 10 mg in BOLERO-2 was
Breast Cancer - FirstWord Reports [PPT]BOLERO 2 - sompu
Download Slides - prIME Oncology
On behalf of the BOLERO-2 Investigators. 3 2. Crowder, RJ. Cancer Res 2009;69:3955-62. 3. Miller, TW. J Clin Invest 2010;. BOLERO-2: Overall Survival. Advanced breast cancer: overall survival results from BOLERO-2. 2: Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, PFS, progression-free survival; TTP, time to progression; ORR, overall BOLERO-2: Everolimus + Exemestane OS, overall survival; QoL, quality of life
